Why Did (TSX:ACB) Reach New Revenue Highs in FY2026?

Highlights

• Aurora Cannabis achieved record annual revenue and record adjusted EBITDA during fiscal 2026.
• International medical cannabis operations, particularly in Europe, contributed significantly to annual growth.
• The divestiture of the Bevo business further streamlined operations around core cannabis activities.

Aurora Cannabis achieved record fiscal 2026 revenue and adjusted EBITDA as European medical cannabis markets expanded, reinforcing its presence within the S&P/TSX Composite Index.

The cannabis sector remained a closely watched area of the Canadian market during fiscal 2026, with Aurora Cannabis (TSX:ACB) reporting record annual revenue and record adjusted EBITDA for the year ended March 31, 2026. As a participant in the S&P/TSX Composite Index-related cannabis sector landscape, the company continued to emphasize medical cannabis operations across Canada and international markets. Fiscal year developments reflected ongoing expansion in regulated medical cannabis jurisdictions, particularly across Europe, while operational changes further sharpened the company’s focus on core cannabis activities.

Medical Cannabis Remains Core Business

Aurora Cannabis operates primarily as a medical cannabis producer and distributor, serving patients through regulated channels in Canada and numerous international jurisdictions. The company maintains cultivation, manufacturing, research, and distribution capabilities designed to meet pharmaceutical-grade standards required in many global markets.

Medical cannabis remains distinct from recreational cannabis due to regulatory oversight, physician involvement, and patient-oriented distribution frameworks. This segment has become increasingly important for producers seeking access to established healthcare channels and international markets with structured regulatory systems.

During fiscal 2026, medical cannabis sales represented a significant component of business activity, with international demand supporting overall revenue growth. The company continued supplying products across Europe, Australia, and other approved jurisdictions while maintaining its domestic medical cannabis presence.

European Markets Drive Expansion

A substantial portion of annual growth originated from European medical cannabis operations. Germany remained one of the most significant markets within the company’s international footprint, supported by evolving regulations and increasing patient access. Poland also contributed to international sales growth as medical cannabis availability expanded within the country.

The European market has become an important destination for Canadian cannabis producers due to stringent product quality requirements and growing acceptance of cannabis-based therapies. Aurora’s production infrastructure and compliance capabilities have enabled participation in these regulated healthcare markets.

Product launches introduced during the fiscal year expanded available offerings in several jurisdictions. New cultivars and formats were added to support patient demand while broadening the company’s presence within established distribution networks.

The continued development of European operations also reflects broader trends within the Cannabis Stocks category, where international medical markets have become increasingly important sources of commercial activity.

Record Fiscal Year Performance

Fiscal 2026 marked a notable year operationally, as annual revenue reached the highest level recorded by the company. Adjusted EBITDA also achieved a record level, reflecting the combined impact of international sales growth and ongoing operational efficiencies.

Revenue contributions from medical cannabis operations across multiple jurisdictions helped support the annual result. International medical cannabis activity represented one of the strongest-performing business segments during the reporting period.

The achievement followed several years of restructuring efforts across the Canadian cannabis industry. Many producers have concentrated on operational efficiency, capacity optimization, and market prioritization as the sector matured following the initial legalization phase.

Within the context of the S&P/TSX Composite Index, cannabis companies have increasingly emphasized sustainable operations and disciplined resource allocation while pursuing growth in regulated medical markets.

Portfolio Simplification Through Bevo Divestiture

Another significant development during the fiscal year involved the completion of the Bevo divestiture. Bevo operated within the controlled-environment agriculture sector and had been part of a broader diversification approach adopted during earlier stages of industry development.

The sale reduced exposure to non-core activities and simplified the corporate structure. Following the transaction, resources became more closely aligned with cannabis cultivation, product development, and distribution activities.

Portfolio simplification has become a recurring theme throughout the cannabis industry as companies refine operational focus around areas directly connected to cannabis production and related healthcare markets.

The divestiture also reflected broader efforts to concentrate business activities on segments most closely associated with medical cannabis demand and international expansion initiatives.

International Distribution Network

Aurora maintains a geographically diverse presence supported by regulatory approvals, distribution partnerships, and cultivation capabilities. International operations encompass multiple continents, enabling access to various patient populations and healthcare systems.

Compliance with pharmaceutical-quality standards remains a central requirement for participation in many overseas markets. Facilities supporting international distribution operate under strict production and quality-control frameworks designed to satisfy country-specific regulatory requirements.

As global medical cannabis adoption continues to evolve, companies with established international infrastructure have been able to participate across several jurisdictions simultaneously. Aurora’s existing network provides access to markets where patient enrollment and product availability continue expanding.

These activities position the company among recognized participants in the broader Cannabis Stocks segment of the Canadian market.

Sector Trends and Market Position

The cannabis sector has experienced substantial transformation since legalization expanded in Canada. Industry participants have increasingly focused on operational efficiency, medical cannabis specialization, and international market development.

Aurora Cannabis (TSX:ACB) has remained active within these trends through ongoing participation in regulated medical cannabis markets and continued expansion of international distribution channels. European markets, particularly Germany and Poland, remained central contributors to business activity during fiscal 2026.

As part of the broader Canadian cannabis landscape connected to the S&P/TSX Composite Index, the company’s fiscal year highlighted the growing significance of international medical cannabis operations and the role of regulated healthcare channels in supporting industry development.